19 Nov 2013 08:07
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Plethora Solutions Holdings Plc Share News (PLE)
PLE Share
Price
PLE Share
News
PLE Share
Chat
PLE Share
Trades
PLE
Live RNS
PLE Share
Charts
PLE Broker
Ratings
PLE Directors
Deals
PLE Financial
Diary
PLE
Fundamentals
PLE Short
Positions
PLE
Media
Plethora Solutions Holdings Plc Information
- There is currently no data for PLE
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Plethora soars on drug development update
Tue, 11th Mar 2014 10:20
Plethora Solutionas saw its value jump by around a third on Tuesday morning after it revealed a meeting with the US Food and Drug Administration (FDA) had resulted in a clear pathway to the successful submission of a new drug application. The application is for PSD 502, a drug used in the treatment of premature ejaculation, an area which the FDA confirmed was one of "high medical need", for which there is a requirement for effective therapy. "The company sees a significant potential market opportunity for PSD 502 both in the US and EU," it said. "Based on [its] internal modelling and pricing input from its US marketing consultant, the company forecasts in excess of $1bn per annum peak prescription sales."It also believes there is "significant value" in PSD 502 for shareholders, and as such, the group's management is looking to unlock that value "as quickly as possible" by bringing negotiations with potential marketing partners to close. It revealed it has received "several expressions of interest" for out-licensing PSD 502 in the US, EU and other territories. "Negotiations are at a more advanced stage with a number of potential marketing partners and the company is hopeful that an announcement will be made in this regard over the coming months," it said. However, it stressed it was not possible to accurately determine the timing of completion or terms of the agreements."The company is also making excellent progress with its preferred manufacturing partner and is hopeful that an announcement will be made within the next month," it added. Shares rose 35.53% to 12.20p by 10:42 Tuesday.NR
More News
20 Sep 2013 12:26
UPDATE 1-New Roche breast cancer drug wins backing in Europe and Japan
* Kadcyla approved in Japan, recommended for approval in EU * EU agency also backs Algeta/Bayer prostate cancer drug LONDON, Sept 20 (Reuters) - Roche's new breast cancer drug Kadcyla was approved in Japan on Friday and recommended for approval in Europe, building on February's U.S. g
Read more12 Apr 2013 11:50
Plethora Solutions Chairman resigns
Plethora Solutions Holdings Chairman Bill Robinson is stepping down from his role at the pharmaceuticals company. Jim Mellon will take over as Chairman with immediate effect temporarily until a successor is found. Robinson, who has been Chairman since 2009, will remain a Non-Executive Director of
Read more18 Mar 2013 14:25
Plethora Solutions secures much needed financing
Plethora Solutions has secured 2.1m pounds in funding after its subsidiary The Urology Co. fell into administration. The funds were raised through the placing of 106.2m new ordinary shares at a price of 2.0p per share, representing an 8.0% interest. It comes after the company announced it was in
Read more14 Feb 2013 08:24
Plethora Solutions shares jump following new equity update
Shares in pharmaceuticals company Plethora Solutions jumped sharply on Thursday after the group reported that it was in 'advanced discussions' with an investor to provide new equity financing to the group. The group, whose share price had recently been declining, added that support was also being s
Read more5 Feb 2013 11:07
Plethora Solutions shares plunge on urgent financing talks
Plethora Solutions is in urgent discussions with third parties to finance the company's working capital purposes. Shares in the pharmaceutical company plummeted 55.00% to 2.25p at 11:18 following Tuesday's announcement. The company said it remained focused on the development of SD502, a drug for
Read more17 Oct 2012 15:15
Plethora's PSD502 drug has mass market potential
Plethora Solutions is definitely a small cap stock to watch and in an exclusive interview with Sharecast, Daniel Stewart analyst Vadim Alexandre has reiterated the bull case for the biotech tiddler. Plethora Solutions has a drug, PSD502, aimed at treating premature ejaculation, which has passed two
Read more15 Mar 2012 12:06
Small caps round-up: HMV, Corero, ANGLE ...
HMV Group, the struggling entertainment media seller, has confirmed that it is still pondering what to do with its live music business. HMV added that a number of parties have indicated an interest in acquiring the business. There has been press speculation recently about who might be interested in
Read more14 Mar 2011 17:36
Plethora's testosterone boost
AIM-quoted sexual health products developer and distributor Plethora Solutions has added the pan-European rights for testosterone replacement treatment Striant SR to the UK rights it already has. Plethora has secured the rights from Columbia Laboratories and it will sell the product through its di
Read more7 Sep 2010 13:48
Small caps round-up: Charlemagne, Highams, Hydro...
Hedge fund manager Charlemagne's assets under management rise have picked up in the past two months to stand at $3.04bn at end August. The modest recovery follows a fall in the first half to $2.8bn, blamed on declining markets. Operating profits were $1.2m, down from $1.3m, with one-off performanc
Read more19 Jul 2010 07:25
Plethora Solutions Launches New Product, hi-Argenol >PLE.LN
LONDON (Dow Jones)--Plethora Solutions Holdings PLC (PLE.LN), a U.K.-based specialty pharmaceutical company, said Monday it has launched a new product, hi-Argenol, for the maintenance and improvement of male sexual health. -Shares closed Friday at 11.75 pence valuing the company at GBP5.21 milli
Read more